The FDA has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech) for subcutaneous injection for all the adult indications as the intravenous formulation of atezolizumab (Tecentriq, Genentech), including non-small cell lung cancer (NSCLC), small cell lung cancer, hepatocellular carcinoma, melanoma and alveolar soft part sarcoma.
The subcutaneous injection of atezolizumab and hyaluronidase-tqjs was evaluated in IMscin001 (ClinicalTrials.gov. Identifier: NCT03735121),